12 › 12.3
12.3 Amyloidosis
Pages 74–77 · open in PDF
Recommendations in this section
- Class ILevel ATreatment with a TTR silencer (vutrisiran) or stabilizer (tafamidis or acoramidis) for patients with variant or wild-type transthyretin cardiac amyloidosis and NYHA classes I–III is recommended to reduce progression of symptoms and the risk of CV hospitalization and all-cause death.
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 74 · PDF
disease. The role of palliative and supportive care spans the entire course of HF, beginning early in the disease, intensifying as the condition progresses, and extending into caregiver bereavement. Evidence supports the use of multidisciplinary palliative care in people with advanced HF to improve patient-reported outcomes (symptom burden, depression, functional status, QoL), but trials do not identify who would benefit most from specialist palliative referral.1063–1065 There are no sufficiently robust multicentre evaluation phase trials to provide generalizable findings.
In pregnant women with HFrEF, it is recommended that non-selective beta-blockers are switched to beta1-selective blockers (metoprolol, bisoprolol) with close mother and
teratogenicity.1074–1076 ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist; SGLT2-I, sodium–glucose co-transporter 2 inhibitor. a Class of recommendation. b Level of evidence.
QoL and reduce symptom burden.1066–1068 HF, heart failure; QoL, quality of life. a Class of recommendation. b Level of evidence.
12.2.1. Hypertrophic cardiomyopathy Patients with HCM may develop HFrEF; in such cases, they should in general be treated as other patients with HFrEF. However, many patients develop symptoms of HF without having HFrEF, and these should be treated according to the cardiomyopathy guidelines (see Supplementary data online, Section S9.2).124
12. Specific conditions 12.1. Pregnancy and heart failure Heart failure in pregnancy requires careful multidisciplinary management.1069–1071 The core components of HF care in pregnancy involves multiple aspects from pre-conception to postpartum (see Supplementary data online, Table S26). Specific recommendations for pre-conception care and management of HF during pregnancy can be found in Recommendation Table 27. For an overview of managing HF in pregnancy, see Supplementary data online, Section S9.1. For a comprehensive and detailed guidance, we refer to the 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy.7
Recommendation Table 27 — Recommendations for heart failure and pregnancy (see Evidence Tables 103–107) Recommendations
Pre-conception care and counselling is recommended for patients with HF to facilitate decision-making surrounding HF treatments, pregnancy, contraception, pre-implantation genetic screening, and assisted reproductive
patients in an advanced HF stage to improve
Cardiomyopathies are a common and specific cause of HF.124 The 2023 ESC Guidelines for the management of cardiomyopathies described cardiomyopathy phenotypes based on structural (e.g. ventricular hypertrophy, dilatation, or scar) and functional (e.g. systolic or diastolic dysfunction) features.124 Detailed recommendations and algorithms for the diagnosis and management of cardiomyopathies are provided in the 2023 ESC Guidelines for the management of cardiomyopathies.124
12.3. Amyloidosis 12.3.1. Epidemiology and diagnosis Cardiac amyloidosis is an infiltrative cardiomyopathy caused by amyloid fibril deposition in the extracellular space, resulting in increased myocardial thickness and stiffness, leading to a restrictive physiology.1077,1078 The two most prevalent forms of CA are immunoglobulin light chain CA (AL-CA) and transthyretin amyloidosis (ATTR). Transthyretin amyloidosis includes the wild-type (>90% of cases), and the hereditary or variant forms.1077 Greater awareness of CA, streamlined diagnostic processes, and the emergence of new treatments has led to an increase in the prevalence of CA.1079,1080 The prevalence of CA is higher in males.1081 Cardiac amyloidosis should be suspected in patients with HF and increased LV wall thickness in the presence of specific red flags (Table 20), particularly in patients aged >65 years. A timely, definitive diagnosis should be obtained as patient outcomes depend largely on early initiation of therapy (particularly in AL-CA). Cardiac amyloidosis can be diagnosed using both invasive and non-invasive diagnostic criteria. Invasive diagnostic criteria apply to all forms of CA, whereas non-invasive criteria are accepted only for transthyretin CA (ATTR-CA).1077 Figure 23 displays the diagnostic work-up and treatment options. For more diagnostic details, the Task Force refers to the 2021 ESC position statement on CA.1077
SGLT2-Is are not recommended during pregnancy due to the risk of foetotocixity or
facilitate communication on end of life and QoL.627 Access to an integrated HF palliative care multidisciplinary team is recommended for
ACE-Is, ARBs, ARNIs, MRAs, ivabradine, and
Proactive discussion regarding HF trajectory, goals of care, and advance care planning is recommended in patients with advanced HF to
foetal events and a lower birth weight.1072,1073
foetus monitoring to reduce the risk of adverse
Recommendation Table 26 — Recommendations for longterm follow-up (see Evidence Tables 101 and 102) Recommendations
Page 75 · PDF
oncohaematology specialists and cardiologists, and whenever possible, patients should be referred to specialized centres.
Table 20 ‘Red flags’ for most common forms of cardiac amyloidosis Category Extracardiac
Bilateral carpal tunnel syndrome
Hypotension or normotension
Pseudo-infarct ECG pattern
Low/decreased QRS voltage relative to LV thickness
Disproportionally elevated
Persistently elevated cardiac troponin levels
Granular sparkling of myocardium
Increased right ventricular wall thickness
Increased interatrial septum
Reduced longitudinal strain
Increased extracellular volume
Abnormal gadolinium kinetics
12.3.2.2. Transthyretin cardiac amyloidosis
if previously hypertensive ECG
NT-proBNP relative to HF severity
with apical sparing pattern CMRb
AL, immunoglobulin light chain; CA, cardiac amyloidosis; CMR, cardiac magnetic resonance; ECG, electrocardiogram; HF, heart failure; LGE, late gadolinium enhancement; LV, left ventricular; NT-proBNP, N-terminal-pro-B-type natriuretic peptide; TTR, transthyretin. a Hereditary TTR-CA. b CMR can be diagnostic for CA.
12.3.2. Disease-specific treatments 12.3.2.1. Immunoglobulin light chain cardiac amyloidosis Treatment of AL-CA includes chemotherapy or autologous stem cell transplantation with careful monitoring of haematological response, cardiac and organ function. Management of AL-CA should be undertaken by a multidisciplinary team involving
Therapeutic agents for ATTR-CA include drugs that inhibit hepatic synthesis of transthyretin (TTR), stabilize the tetramer, or disrupt the amyloid fibrils. Based on the results of large RCTs, the Task Force recommends treatment with a TTR stabilizer or a TTR silencer with proven safety and efficacy on morbidity and mortality, in patients with either wild-type or hereditary ATTR-CA and a clinical history of HF with NYHA classes I–III. These drugs include the TTR stabilizers tafamidis and acoramidis and the TTR silencer vutrisiran.1082–1084 In the ATTR-ACT trial, tafamidis reduced all-cause death and CV hospitalizations over 30 months in both hereditary and wildtype ATTR-CA.1082 Benefits on functional capacity occurred within 6 months, whereas reduction in all-cause death was observed from 18 months onwards. It showed limited impact in advanced cases (NYHA class III). In the ATTRibute-CM trial, after 30 months of treatment, acoramidis was superior to placebo in a hierarchical analysis (allcause death, CV hospitalization, change from baseline in NT-proBNP, and change from baseline in 6-min walk test).1083 Although it did not independently lower death at 30 months, it did reduce the combined endpoint of all-cause death or CV hospitalizations. Notably, survival rates in the placebo arm were higher than in the treatment group of ATTR-ACT, possibly reflecting earlier disease stage and the improvements in earlier diagnosis and access to specialist care. Furthermore, in the open-label extension study, early initiation and continuous use of acoramidis significantly reduced death at 42 months, as compared with the later initiation of acoramidis.1085 In the APOLLO-B trial, patisiran (i.v.) reduced functional decline over 12 months.1086 However, no data are available regarding morbidity and mortality. In the HELIOS-B trial, vutrisiran (subcutaneous) reduced the risk of the combined endpoint of allcause death and recurrent CV events vs placebo.1084 Also, the risk of all-cause death through 42 months was lowered with vutrisiran. These benefits persisted regardless of background tafamidis use at baseline (∼40% of the trial population).1084 None of the studies provided a head-to-head comparison of TTR silencers vs stabilizers nor a head-to-head comparison of monotherapy vs combination therapies. Several studies are ongoing with further therapeutical options acting on gene editing, RNA silencing, or the repletion of amyloid deposits, and might change the management of ATTR-CA in the future.
12.3.3. Treatment of heart failure and cardiovascular comorbidities Evidence for the use of FMT in patients with CA is still scarce and limited to post-hoc analyses of RCTs or retrospective studies.1087–1092 Patients with CA may poorly tolerate standard HF therapies due to restrictive physiology, autonomic dysfunction, atrioventricular conduction disturbance, and kidney impairment. Diuretics remain central for congestion management but must be used cautiously within a narrow euvolaemic window.1089,1090 Increasing diuretic dose is a signal of disease progression with worse outcomes.1093,1094 Evidence supports the safety and benefit of SGLT2-Is.73,1089–1092 MRA might also be useful.1092
Page 76 · PDF
Figure 23 Diagnosis and treatment of cardiac amyloidosis in heart failure patients. 99mTc, technetium-99m; AL, immunoglobulin light chain; AL-CA, immunoglobulin light chain cardiac amyloidosis; ATTR-CA, transthyretin cardiac amyloidosis; CA, cardiac amyloidosis; CMR, cardiac magnetic resonance; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; HMDP, hydroxymethylene diphosphonate; LVH, left ventricular hypertrophy; PYP, pyrophosphate; SPECT, single-photon emission computed tomography; TTR, transthyretin. a See Table 20. bUsually an extracardiac biopsy is performed first. cPerform TTR genetic testing. dDiagnosis will be based on the results from the individualized approach.
Page 77 · PDF
Beta-blockers and ACE-I/ARNI/ARB use requires caution, individualized decisions, and close monitoring. In patients with CA and AF, anticoagulation is indicated regardless of CHA2DS2-VA score, due to high thromboembolic risk.1077,1095–1097 Transoesophageal echocardiography is necessary before cardioversion to exclude intracardiac thrombus, regardless of the duration of anticoagulation before the procedure.1098 The use of digoxin is generally discouraged due to high risk of toxicity. Few patients with CA and advanced symptoms may be eligible for heart transplantation in line with international criteria.580
reserved for fulminant, non-infectious forms of myocarditis to stabilize the patients.8
12.5. Adult congenital heart disease
Recommendation Table 28 — Recommendations for cardiac amyloidosis (see Evidence Tables 108–111) Recommendation
Treatment with a TTR silencer (vutrisiran) or with variant or wild-type transthyretin cardiac amyloidosis and NYHA classes I–III is recommended to reduce progression of symptoms and the risk of CV hospitalization and all-cause death.1082–1084 CV, cardiovascular; NYHA, New York Heart Association; TTR, transthyretin. a Class of recommendation. b Level of evidence.
12.4. Myocarditis 12.4.1. Epidemiology and diagnosis The contribution of myocarditis as a cause of HF is estimated to be less than 5%.1099 When patients with myocarditis present with DHF, LVEF <40%, life-threatening arrhythmias (ventricular tachycardia/fibrillation, third-degree atrioventricular block), and/or extensive LGE on CMR, they should be viewed as high risk.1100,1101 High-risk patients may require an endomyocardial biopsy in order to tailor treatment,8 whereas lower-risk patients may be examined with CMR imaging. The clinical presentation ranges from impaired LV function to refractory HF, CS (fulminant myocarditis), or sudden cardiac arrest. Some patients present primarily with arrhythmias. Prognosis depends on initial presentation.1100,1101 Patients with fulminant myocarditis should be transferred or discussed with a center that has the possibility to perform endomyocardial biopsy and provide MCS support. High-risk patients have a high mortality and may need temporary MCS and/or in the long term heart transplantation or durable MCS.1102–1104
12.4.2. Treatment The treatment algorithm is reported in the 2025 ESC Guidelines for the management of myocarditis and pericarditis.8 Patients with myocarditis and HFrEF should be empirically treated with FMT for HFrEF (see Section 7). Routine immunosuppression is not recommended in patients with preserved LVEF and should be
stabilizer (tafamidis or acoramidis) for patients
13. Key messages New classifications • Heart failure has been redefined with two distinct phenotypes: ⚬ HFrEF: LVEF <50% + symptoms and/or signs of HF. ⚬ HFpEF: LVEF ≥50% + symptoms and/or signs of HF + objective evidence of cardiac structural and/or functional abnormalities. • Stages of HF (A–D) have been adopted: ⚬ Stage A: individuals at risk for HF but without signs, symptoms, and cardiac abnormalities. ⚬ Stage B: pre-HF, defined as the presence of cardiac abnormalities without signs and symptoms of HF. ⚬ Stage C: symptomatic HF, defined as the presence of cardiac abnormalities and current or prior signs and/or symptoms of HF. ⚬ Stage D: advanced HF. • New classifications for medical and interventional HF therapies have been introduced. The terms are designed to be dynamic and may therefore remain contemporary over time: ⚬ FMT—Foundational medical therapy: medical therapies for unselected patients with HF with Class I recommendation for reducing HFH and/or death. ⚬ AMT—Additional medical therapy: medical therapies with Class IIa/IIb recommendations or Class I recommendations for improving symptoms/QoL or reducing morbidity or mortality in specific subsets of patients with HF. ⚬ GDIT—Guideline-directed interventional therapy: all guideline-recommended implantable devices or interventional therapies. Prevention of heart failure • A strict control of HF risk factors is recommended to prevent HF.
Adult congenital heart disease is a heterogeneous group of structural heart abnormalities varying in complexity. There has been an improvement in survival with contemporary care.1105 Consequently, HF in ACHD is increasingly common,1106,1107 and represents a major contributor to morbidity and mortality, accounting for 26%–46% of deaths, with higher rates seen in more complex lesions.1108–1110 Managing HF in ACHD poses specific challenges related to original anatomy, presence of haemodynamic lesions, previous interventions, and extracardiac complications such as kidney and liver dysfunction.1111,1112 Specific indications on the management of these patients are reported in the 2020 ESC Guidelines for the management of adult congenital heart disease1111 and in a recent ESC clinical consensus statement.1113